This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zurich Heart Center Reports Excellent Early Clinical Experience With ESVS® Mesh At International Society Of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

Manny Villafaña, Chairman and CEO of Kips Bay Medical Inc. (NASDAQ:KIPS) announced today that Prof. Michele Genoni, MD, Chief of Cardiovascular Surgery of the Triemli Hospital, Zurich, Switzerland, presented his center’s early clinical experience with the eSVS ® Mesh device at the 14 th Annual meeting of the ISMICS in Los Angeles, CA.

Since 2011, Prof. Genoni and his surgical team have implanted the eSVS Mesh in twenty (20) patients undergoing off-pump coronary artery bypass procedures (“OPCAB"). All patients received two arterial bypass grafts, using the left and right internal mammary arteries, and one saphenous vein graft (“SVG”), treated with the eSVS Mesh device, to the right coronary artery. The Kips Bay Medical eSVS Mesh is a knitted, nitinol prosthesis that is designed to fit around the outside of the saphenous vein so as to minimize the undesirable over-expansion which can cause graft failure. All bypass grafts were evaluated with computed tomography (“CT”) angiograms performed prior to the patient’s discharge from the hospital.

The data from these patients demonstrated excellent flow in the SVG grafts treated with the eSVS Mesh device. The results from these twenty patients showed that 95% of the saphenous vein grafts treated with the eSVS Mesh were open, or patent, and 100% of the arterial grafts were open.

Commenting on these results Prof. Genoni said, “We are very pleased with these early results utilizing the eSVS Mesh. OPCAB surgery can be more technically demanding and the eSVS Mesh is easy to use and fits well within our OPCAB program. Our next step is to follow these patients to collect longer term data.” Additionally, Manny Villafana, CEO, Founder and Chairman of Kips Bay Medical stated, “We congratulate Prof. Genoni and his team on their excellent initial results. These results reinforce and affirm the product and process improvements that we implemented after our first international trial. Kips Bay Medical remains committed to providing longer term follow-up evaluation on the safety and performance of the eSVS Mesh in CABG procedures. ”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs